Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 453120, 15 pages
http://dx.doi.org/10.1155/2008/453120
Research Article

Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR- Agonists

Department of Neurobiology and Developmental Sciences, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

Received 10 March 2008; Accepted 5 May 2008

Academic Editor: Michael Racke

Copyright © 2008 Catherine Gurley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Farina, F. Aloisi, and E. Meinl, “Astrocytes are active players in cerebral innate immunity,” Trends in Immunology, vol. 28, no. 3, pp. 138–145, 2007. View at Publisher · View at Google Scholar
  2. F. Aloisi, “Immune function of microglia,” Glia, vol. 36, no. 2, pp. 165–179, 2001. View at Publisher · View at Google Scholar
  3. U.-K. Hanisch, “Microglia as a source and target of cytokines,” Glia, vol. 40, no. 2, pp. 140–155, 2002. View at Publisher · View at Google Scholar
  4. Y. Dong and E. N. Benveniste, “Immune function of astrocytes,” Glia, vol. 36, no. 2, pp. 180–190, 2001. View at Publisher · View at Google Scholar
  5. S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006. View at Publisher · View at Google Scholar
  6. T. Kaisho and S. Akira, “Pleiotropic function of Toll-like receptors,” Microbes and Infection, vol. 6, no. 15, pp. 1388–1394, 2004. View at Publisher · View at Google Scholar
  7. S. Carpenter and L. A. J. O'Neill, “How important are Toll-like receptors for antimicrobial responses?” Cellular Microbiology, vol. 9, no. 8, pp. 1891–1901, 2007. View at Publisher · View at Google Scholar
  8. G. Sitia, M. Iannacone, S. Müller, M. E. Bianchi, and L. G. Guidotti, “Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 100–107, 2007. View at Publisher · View at Google Scholar
  9. A. M. Krieg and J. Vollmer, “Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity,” Immunological Reviews, vol. 220, no. 1, pp. 251–269, 2007. View at Publisher · View at Google Scholar
  10. B. J. Marsland and M. Kopf, “Toll-like receptors: paving the path to T cell-driven autoimmunity?” Current Opinion in Immunology, vol. 19, no. 6, pp. 611–614, 2007. View at Publisher · View at Google Scholar
  11. T. Kielian, “Toll-like receptors in central nervous system glial inflammation and homeostasis,” Journal of Neuroscience Research, vol. 83, no. 5, pp. 711–730, 2006. View at Publisher · View at Google Scholar
  12. P. A. Carpentier, D. S. Duncan, and S. D. Miller, “Glial toll-like receptor signaling in central nervous system infection and autoimmunity,” Brain, Behavior, and Immunity, vol. 22, no. 2, pp. 140–147, 2008. View at Publisher · View at Google Scholar
  13. P. H. Larsen, T. H. Holm, and T. Owens, “Toll-like receptors in brain development and homeostasis,” Science's STKE, vol. 2007, no. 402, p. pe47, 2007. View at Publisher · View at Google Scholar
  14. A. A. Babcock, M. Wirenfeldt, T. Holm et al., “Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation,” Journal of Neuroscience, vol. 26, no. 49, pp. 12826–12837, 2006. View at Publisher · View at Google Scholar
  15. K. A. Kigerl, W. Lai, S. Rivest, R. P. Hart, A. R. Satoskar, and P. G. Popovich, “Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury,” Journal of Neurochemistry, vol. 102, no. 1, pp. 37–50, 2007. View at Publisher · View at Google Scholar
  16. T. Kielian and P. D. Drew, “Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation,” Journal of Neuroscience Research, vol. 71, no. 3, pp. 315–325, 2003. View at Publisher · View at Google Scholar
  17. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar
  18. R. Kapadia, J.-H. Yi, and R. Vemuganti, “Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists,” Frontiers in Bioscience, vol. 13, no. 5, pp. 1813–1826, 2008. View at Publisher · View at Google Scholar
  19. R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005. View at Publisher · View at Google Scholar
  20. M. T. Heneka and G. E. Landreth, “PPARs in the brain,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1031–1045, 2007. View at Publisher · View at Google Scholar
  21. P. D. Drew, J. Xu, P. D. Storer, J. A. Chavis, and M. K. Racke, “Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders,” Neurochemistry International, vol. 49, no. 2, pp. 183–189, 2006. View at Publisher · View at Google Scholar
  22. A. Bernando and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006. View at Publisher · View at Google Scholar
  23. T. Kielian, M. McMahon, E. D. Bearden, A. C. Baldwin, P. D. Drew, and N. Esen, “S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2),” Journal of Neurochemistry, vol. 90, no. 5, pp. 1163–1172, 2004. View at Publisher · View at Google Scholar
  24. N. K. Phulwani, D. L. Feinstein, V. Gavrilyuk, C. Akar, and T. Kielian, “15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-γ-independent pathway,” Journal of Neurochemistry, vol. 99, no. 5, pp. 1389–1402, 2006. View at Publisher · View at Google Scholar
  25. Q. Jiang, M. Heneka, and G. E. Landreth, “The role of peroxisome proliferator-activated receptor-γ (PPARγ) in Alzheimer's disease: therapeutic implications,” CNS Drugs, vol. 22, no. 1, pp. 1–14, 2008. View at Google Scholar
  26. J. Xu and P. D. Drew, “Peroxisome proliferator-activated receptor-γ agonists suppress the production of IL-12 family cytokines by activated glia,” Journal of Immunology, vol. 178, no. 3, pp. 1904–1913, 2007. View at Google Scholar
  27. P. D. Storer, J. Xu, J. Chavis, and P. D. Drew, “Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 113–122, 2005. View at Publisher · View at Google Scholar
  28. A. Bernardo, G. Levi, and L. Minghetti, “Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-Δ12,14-prostaglandin J2 in the regulation of microglial functions,” European Journal of Neuroscience, vol. 12, no. 7, pp. 2215–2223, 2000. View at Publisher · View at Google Scholar
  29. T. V. Petrova, K. T. Akama, and L. J. Van Eldik, “Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4668–4673, 1999. View at Publisher · View at Google Scholar
  30. C. S. Jack, N. Arbour, J. Manusow et al., “TLR signaling tailors innate immune responses in human microglia and astrocytes,” Journal of Immunology, vol. 175, no. 7, pp. 4320–4330, 2005. View at Google Scholar
  31. P. A. Carpentier, W. S. Begolka, J. K. Olson, A. Elhofy, W. J. Karpus, and S. D. Miller, “Differential activation of astrocytes by innate and adaptive immune stimuli,” Glia, vol. 49, no. 3, pp. 360–374, 2005. View at Publisher · View at Google Scholar
  32. J. K. Olson and S. D. Miller, “Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs,” Journal of Immunology, vol. 173, no. 6, pp. 3916–3924, 2004. View at Google Scholar
  33. N. Esen, F. Y. Tanga, J. A. DeLeo, and T. Kielian, “Toll-like receptor 2 (TLR2) mediates astrocyte activation in response to the Gram-positive bacterium Staphylococcus aureus,” Journal of Neurochemistry, vol. 88, no. 3, pp. 746–758, 2004. View at Publisher · View at Google Scholar
  34. N. Esen and T. Kielian, “Central role for MyD88 in the responses of microglia to pathogen-associated molecular patterns,” Journal of Immunology, vol. 176, no. 11, pp. 6802–6811, 2006. View at Google Scholar
  35. N. Esen and T. Kielian, “Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs),” Journal of Neuroinflammation, vol. 4, article 10, 2007. View at Publisher · View at Google Scholar
  36. N. Esen, D. Shuffield, M. M. Syed, and T. Kielian, “Modulation of connexin expression and gap junction communication in astrocytes by the gram-positive bacterium S. aureus,” Glia, vol. 55, no. 1, pp. 104–117, 2007. View at Publisher · View at Google Scholar
  37. M. Bsibsi, R. Ravid, D. Gveric, and J. M. van Noort, “Broad expression of Toll-like receptors in the human central nervous system,” Journal of Neuropathology & Experimental Neurology, vol. 61, no. 11, pp. 1013–1021, 2002. View at Google Scholar
  38. T. Kielian, N. Esen, and E. D. Bearden, “Toll-like receptor 2 (TLR2) is pivotal for recognition of S. aureus peptidoglycan but not intact bacteria by microglia,” Glia, vol. 49, no. 4, pp. 567–576, 2005. View at Publisher · View at Google Scholar
  39. S. C. Byram, M. J. Carson, C. A. DeBoy, C. J. Serpe, V. M. Sanders, and K. J. Jones, “CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation,” Journal of Neuroscience, vol. 24, no. 18, pp. 4333–4339, 2004. View at Publisher · View at Google Scholar
  40. M. J. Carson, T. V. Bilousova, S. S. Puntambekar, B. Melchior, J. M. Doose, and I. M. Ethell, “A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease,” Neurotherapeutics, vol. 4, no. 4, pp. 571–579, 2007. View at Publisher · View at Google Scholar
  41. N. P. Turrin and S. Rivest, “Molecular and cellular immune mediators of neuroprotection,” Molecular Neurobiology, vol. 34, no. 3, pp. 221–242, 2006. View at Publisher · View at Google Scholar
  42. D. Gosselin and S. Rivest, “Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system,” Brain, Behavior, and Immunity, vol. 21, no. 3, pp. 281–289, 2007. View at Publisher · View at Google Scholar
  43. K. Sriram and J. P. O'Callaghan, “Divergent roles for tumor necrosis factor-α in the brain,” Journal of NeuroImmune Pharmacology, vol. 2, no. 2, pp. 140–153, 2007. View at Publisher · View at Google Scholar
  44. T. Kielian, “Immunopathogenesis of brain abscess,” Journal of Neuroinflammation, vol. 1, article 16, 2004. View at Publisher · View at Google Scholar
  45. R. Nau and W. Brück, “Neuronal injury in bacterial meningitis: mechanisms and implications for therapy,” Trends in Neurosciences, vol. 25, no. 1, pp. 38–45, 2002. View at Publisher · View at Google Scholar
  46. R. N. Saha and K. Pahan, “Tumor necrosis factor-α at the crossroads of neuronal life and death during HIV-associated dementia,” Journal of Neurochemistry, vol. 86, no. 5, pp. 1057–1071, 2003. View at Publisher · View at Google Scholar
  47. R. M. Ransohoff, L. Liu, and A. E. Cardona, “Chemokines and chemokine receptors: multipurpose players in neuroinflammation,” International Review of Neurobiology, vol. 82, pp. 187–204, 2007. View at Publisher · View at Google Scholar
  48. A. D. Luster, “Chemokines—chemotactic cytokines that mediate inflammation,” The New England Journal of Medicine, vol. 338, no. 7, pp. 436–445, 1998. View at Publisher · View at Google Scholar
  49. N. M. Rebenko-Moll, L. Liu, A. Cardona, and R. M. Ransohoff, “Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details,” Current Opinion in Immunology, vol. 18, no. 6, pp. 683–689, 2006. View at Publisher · View at Google Scholar
  50. T. Kielian, B. Barry, and W. F. Hickey, “CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses,” Journal of Immunology, vol. 166, no. 7, pp. 4634–4643, 2001. View at Google Scholar
  51. M. D. Bell, D. D. Taub, S. J. Kunkel et al., “Recombinant human adenovirus with rat MIP-2 gene insertion causes prolonged PMN recruitment to the murine brain,” European Journal of Neuroscience, vol. 8, no. 9, pp. 1803–1811, 1996. View at Publisher · View at Google Scholar
  52. R. M. Ransohoff, P. Kivisäkk, and G. Kidd, “Three or more routes for leukocyte migration into the central nervous system,” Nature Reviews Immunology, vol. 3, no. 7, pp. 569–581, 2003. View at Publisher · View at Google Scholar
  53. X. Zhang, J. M. Wang, W. H. Gong, N. Mukaida, and H. A. Young, “Differential regulation of chemokine gene expression by 15-deoxy-Δ12,14 prostaglandin J2,” Journal of Immunology, vol. 166, no. 12, pp. 7104–7111, 2001. View at Google Scholar
  54. Q. Si, M.-L. Zhao, A. C. Morgan, C. F. Brosnan, and S. C. Lee, “15-deoxy-Δ12,14,-prostaglandin J2 inhibits IFN-inducible protein 10/CXC chemokine ligand 10 expression in human microglia: mechanisms and implications,” Journal of Immunology, vol. 173, no. 5, pp. 3504–3513, 2004. View at Google Scholar
  55. T. Kielian, “Microglia and chemokines in infectious diseases of the nervous system: views and reviews,” Frontiers in Bioscience, vol. 9, pp. 732–750, 2004. View at Publisher · View at Google Scholar
  56. D. J. Mahad and R. M. Ransohoff, “The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE),” Seminars in Immunology, vol. 15, no. 1, pp. 23–32, 2003. View at Publisher · View at Google Scholar
  57. C. J. Auch, R. N. Saha, F. G. Sheikh, X. Liu, B. L. Jacobs, and K. Pahan, “Role of protein kinase R in double-stranded RNA-induced expression of nitric oxide synthase in human astroglia,” FEBS Letters, vol. 563, no. 1–3, pp. 223–228, 2004. View at Publisher · View at Google Scholar
  58. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar
  59. D. S. Straus and C. K. Glass, “Cyclopentenone prostaglandins: new insights on biological activities and cellular targets,” Medicinal Research Reviews, vol. 21, no. 3, pp. 185–210, 2001. View at Publisher · View at Google Scholar
  60. L. Van Gaal and A. J. Scheen, “Are all glitazones the same?” Diabetes/Metabolism Research and Reviews, vol. 18, supplement 2, pp. S1–S4, 2002. View at Publisher · View at Google Scholar
  61. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor ? agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Google Scholar
  62. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  63. C. Dello Russo, V. Gavrilyuk, G. Weinberg et al., “Peroxisome proliferator-activated receptor ? thiazolidinedione agonists increase glucose metabolism in astrocytes,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 5828–5836, 2003. View at Publisher · View at Google Scholar
  64. D. L. Feinstein, A. Spagnolo, C. Akar et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005. View at Publisher · View at Google Scholar
  65. Y. Kodera, K. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato, “Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33201–33204, 2000. View at Publisher · View at Google Scholar
  66. P. D. Drew and J. A. Chavis, “The cyclopentone prostaglandin 15-deoxy-Δ12,14 prostaglandin J2 represses nitric oxide, TNF-α, and IL-12 production by microglial cells,” Journal of Neuroimmunology, vol. 115, no. 1-2, pp. 28–35, 2001. View at Publisher · View at Google Scholar
  67. D. W. Gilroy, P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby, “Inducible cyclooxygenase may have anti-inflammatory properties,” Nature Medicine, vol. 5, no. 6, pp. 698–701, 1999. View at Publisher · View at Google Scholar
  68. T. Lawrence, D. A. Willoughby, and D. W. Gilroy, “Anti-inflammatory lipid mediators and insights into the resolution of inflammation,” Nature Reviews Immunology, vol. 2, no. 10, pp. 787–795, 2002. View at Publisher · View at Google Scholar
  69. C. L. Langrish, B. S. McKenzie, N. J. Wilson, R. de Waal Malefyt, R. A. Kastelein, and D. J. Cua, “IL-12 and IL-23: master regulators of innate and adaptive immunity,” Immunological Reviews, vol. 202, no. 1, pp. 96–105, 2004. View at Publisher · View at Google Scholar
  70. G. Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity,” Nature Reviews Immunology, vol. 3, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar
  71. T. Kielian, M. M. Syed, S. Liu et al., “The synthetic PPAR-γ agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses,” Journal of immunology, vol. 180, no. 3, pp. 5004–5016, 2008. View at Google Scholar
  72. A. von Knethen, M. Soller, and B. Brüne, “Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 55, no. 1, pp. 19–25, 2007. View at Publisher · View at Google Scholar
  73. R. Arnold and W. König, “Peroxisome proliferator-activated receptor-γ agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells,” Virology, vol. 350, no. 2, pp. 335–346, 2006. View at Publisher · View at Google Scholar
  74. D. Liu, B. X. Zeng, S. H. Zhang, and S. L. Yao, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia,” Inflammation Research, vol. 54, no. 11, pp. 464–470, 2005. View at Publisher · View at Google Scholar
  75. J. M. Kaplan, J. A. Cook, P. W. Hake, M. O'Connor, T. J. Burroughs, and B. Zingarelli, “15-deoxy-Δ12,14-prostaglandin J2 (15D-PGJ2), a peroxisome proliferator activated receptor γ ligand, reduces tissue leukosequestration and mortality in endotoxic shock,” Shock, vol. 24, no. 1, pp. 59–65, 2005. View at Publisher · View at Google Scholar
  76. S. H. Ramirez, D. Heilman, B. Morsey, R. Potula, J. Haorah, and Y. Persidsky, “Activation of peroxisome proliferator-activated receptor γ (PPARγ) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes,” Journal of immunology, vol. 180, no. 3, pp. 1854–1865, 2008. View at Google Scholar